Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With its solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications. He is also Managing Partner of Salto Partners, a management consulting firm headquartered in the DC metro area. He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales and operations. Clients are operating in the high tech and life sciences space. Dr. Scherer holds a PhD in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! He is married and the proud father of one son.

Precision Medicine

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Mind Genomics

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Dr. Sergey Zhuplatov is a Medical Director of the Metabolic Strategy and Development of AstraZeneca LP. Fort Washington, PA. He was graduated as MD at the Izhevsk State Medical Academy in Russia before finishing his fellowship in Internal Medicine/Endocrinology at Moscow Academy of Post diploma Education and Moscow Medical Institute of Transplantology in 1986. He accepted tenure and leading clinical consultant position in Endocrinology/Cardiology clinic at his Alma Mater ISMA. At this time, he started his Ph.D. dissertation in Cardiology with prevention of progressive CV events in Diabetes Mellitus Patients as the main topic, which was perfectly defended at Ural State Medical Academy on 1991. Dr. Zhuplatov has been working as an Assistant Professor and practicing physician till his emigration to the USA in 2002 as an exceptional ability person visa waiver. Before that he worked 2 years as a Medical Scientific Consultant for Merck S&D Co., and also as a Chief Medical Officer in Private Medical Clinic for 2 years. He published different works in Internal Medicine, Lipidology, Endocrinology, and Cardiology. He continued his scientific work in University of Utah Medical School till his merge to Pharmaceutical Industry in 2008. Since then he is working in Cardio/Metabolic area of Medical Affairs and Clinical Development of Bristol-Meyers Squibb and AstraZeneca Co. He currently resides in Bucks County PA with his wife Irina, Industrial Psychology Ph.D. They both like fine arts, travel, and reading. His two sons are graduate students in Economy and Medicine.

Diabetology,Lipids,Ischemic Heart Disease, Microcirculation,Echocardiography,Obesity.

Dr. Luigi Maselli received the Distinguished Doctor Award at San Raffaele University of Rome in honor of his significant contribution to Lifestyle Medicine in Italy. He is a neuroimmunologist with a PhD in Neurosciences and works as a Research Fellow at Sapienza University of Rome – School of Medicine and Dentistry and as a Visiting Fellow at Gabriele d’Annunzio University of Chieti-Pescara – School of Health Sciences. Dr. Maselli is the founding President of the Italian Lifestyle Medicine Association (ILMA). He is active in patient care, research, speaking, teaching and writing, and wrote the first Italian book on Lifestyle Medicine. After establishing his connection with the Institute of Lifestyle Medicine at Harvard Medical School, where he fell in love with Lifestyle Medicine, he established Lifestyle Medicine programs in several Italian universities. His overwhelming enthusiasm for life and propensity for helping others reflect the values that make Lifestyle Medicine unique- for the treatment and prevention of lifestyle-related chronic diseases.

Internal Medicine

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, cell science, Trace elemts, biology, Biomedical Laboratory

Gillie Gabay is a systems science expert. Ms. Gabay is a systemic organizational consultant who leads changes that aim at creating an optimal fit between business strategies and organizational strategies. She studies health psychology, at the individual, group and system level researching behavioral processes in health, illness and healthcare. Ms. Gabay promotes a systemic integrated approach where multiple views are accounted for: The view of the health system, the view of the patient and the view of the clinician. She is a senior lecturer at the Organizational Consulting Graduate Program at the College of Management in Israel

Mind Genomics

Roukos DH, Ioannina University, Greece. Dimitrios Roukos, MD (Athens University, Greece), PhD (J.W.Goethe University, Frankfurt a.M., Germany), has moved his scientific interest after 25 years of reductionist medicine to network biology-based systems medicine. Assessing the clinical limitations of current traditional medicine to cure in the future incurable diseases such as cancer, has focused over the last 5 years on human cancer genome both structural variation and functional heterogeneity. His emerging goal is to understand how inherited and somatic mutations, epigenome, transcriptome and interactome abnormalities change chromatin dynamic states and gene expression. Emerging evidence suggests that this gene dysfunction and deregulation of cell signalling pathways drive tumorigenesis and metastasis. His ultimate goal is to approach next-generation anticancer drugs and biomarkers to future achievement of personalized medicine and network biology-based managment of cancer.Publication metrics: > 200 papers with ~ 5,000 citations (h=55) in PubMed, ISI, Scopus and current editor of two eBooks on personalized management of cancer and cancer genome heterogeneity-based treatment of cancer. Currently is key evaluator in European Commission (FP7 Systems Medicine area) and French National Research Agency (22 billion euros) participating in experts panel meeting in Brussels and Paris (end 2011) for the selection of best projects. He is leader of Translational Research in European Union Network of Excellence (EUNE) for gastric cancer and Personalized Cancer Genomic Medicine, Biobank in Ioannina University (Greece). He has been invited speaker and consensus member in multiple International Cancer Meetings. He serves as Editor-in-Chief, Associate Editor and Editorial board member in 20 influential journals.

Assessing limitations of conventional reductionist medicine, he have shifted to multi-scale genes, proteins, molecules, DNA, and RNA interactions in physical and functional networks. Revolutionary NGS technologies provide mow sequencing of DNA (whole genome, exome), transcriptome (RNA-seq, Chip-seq), epigenome (BS-seq) and also along with novel techniques (living cells imaging and computational models) also deeper insights into the grand challenge of interactome (multidimensional spatiotemporal protein-protein interactions). Integrating all these experimental data (omics, living-cells imaging, 3D-genome resolution and intra- and inter-cellular differentiation mapping) and large-scale clinical data into computational models, deep understanding of a personal genome code-lifestyle interactions network is beginning to be shaped. The perspectives of future medicine based on clinical genome and systems science are now rationally excellent for revolutionizing healthcare.

Anatoly Victorovich Skalny was born on the 12th of April, 1962 in Ivano-Frankovsk-City (Ukrain). Graduated school in Olyka village of Volynskaya oblast and medical faculty of Ivano-Frankovsk Medicine State Institute (1985) with honours. Began to carry aout scientific researches from 1979 in a student scientific society under the leadership of professor G.A. Babenko, a leading specialist in medicine elementology in Soviet Union. Ph.D. in Medicine (from 1990). Member of Council on trace elements in agriculture, biology and medicine in AS USSR and RAS (from 1987), Executive Committee of Moscow department of physicians-assistants' Society (from 1989), Boards in ecology and natural recources, science, culture and public health Political Consulting Council under the President of Russian Federation (from 1997), Member of advisory committee in ecology at Moscow City Parliament, co-founder of public movement "Healthy City - health of moscovites" (from 1998). In 1985–1991 worked as a research assistant, Junior Researcher and Researcher in department of restoration treatment of children with cerebral paralysis of Research Institute of common and justice psychiatry by V.P.Serbsky of HM USSR, department of alcoholism genetics in State Scientific Center of narcology of HM USSR. In 1988 he founded scientific-medical center "Element" that is the base to carry out researches of biosubstrates elemental content for medicine purposes during 11 years (for population, health and sanitary-hygienic organizations), scientific institutes such as Research Institute of pediatrics of RAMS, Center for perinatology, obstetrics and gynaecology of HM RF, Navy Institute of Hygiene of HM RF, colleges of medicine of Moscow, Ivanovo, Irkutsk, N.Novgorod and other cities. Center for Biotic Medicine, - autonomous non-profit organization (CBM), - was founded by A.V.Skalny in 1995 that is the unique scientific-methodical Center for problems of applied medicine elementology in RF and UIS. On the 19 of January, 2001 "Russian Society of Medicine Elementology" (RUSTEM) was founded to provide the strongest evolution of trace elements paradigm. During the period from 1982 about 200 scientific articles and thesis' were published by A.V.Skalny in special issues in Russia and abroad as well as manuals and mini-monographs in problems of practical medicine elementology. A.V. Skalny with co-authors registered 3 certificates of authorship and 3 patents of RF and Ukrain in the branch of producing new biologically active compounds of trace elements (Se, Zn) to treat and make prophylaxis of human diseases, methods of treatments of zinc deficiency states, alcohol coma and schysophrenia. To date new line in medicine and ecology, - medicine elementology, - is established by A.V. Skalny in Russia and UIS and developed successfully that studies peculiarities of human organism elemental composition in different functional states and disorders and the ways to increase organism adaptative functions with the help of trace elements metabolism correction. In SMC "Element" and CBM more than 20 Ph.D.'s and 5 D.Sc.' in medicine and biology were trained who develop different applied aspects of medicine elementology in branches of perinatology, endocrinology, urology, nephrology, labour medicine, nutrition hygiene, narcology in leaders clinics of Russia, Ukrain, Kazakhstan, Uzbekistan. In 1998-1999 production of new generation of effective major and trace elements' preparations (compounds with aspartic, spirulina) was organized under the methodic management of organizations headed by A.V. Skalny that awoke interest of specialists and consumers home and abroad. On April, 2003 A.V. Skalny opened the first chair of nutritiology and bioelementology in Russia and became its leader. From September, 2003 Bioelementology Institute, the first in the world, being founded by A.V. Skalny under support of Orenburg State University rectorate and RUSTEM, began its activity.

Internal Medicine (General Medicine)

Farid Menaa is an inter- and multi-disciplinar professional (director, professor, researcher and entrepreneur) with increasing international recognition. His strong background is mainly related to medecine, biology, pharmaceutical sciences, biochemistry, biophysics and genetics. Dr. Menaa has studied and worked for/with several reputed institutions worldwide, including Sorbonne (Paris, France), CNRS (France), INSERM (France), CEA (Ministry of Defence, France), SKCC/sanford-Burnham Medical Research Institute (USA), Schools of Medecine of Paris (France), Wuerzburg (Germany) and Campinas (Unicamp, Brazil). Among other responsibilities he carried out, Dr. Menaa has been, for several years, the R&D director of Fluorotronics, Inc. San Diego, CA, USA, a premier company specialized in fluorine chemistry and nanotechnology. Dr. Menaa was also a principal investigator in projects related to Oncology, Dermatology, Stem Cells, Genetics and Hematology. Dr. Menaa is currently an international consulting expert in healthcare and biosystems for a number of organizations and serves as an editorial board member for a large number of esteemed journals in medecine, sciences and business. Dr. Menaa holds dozen of peer-reviewed manuscripts and is a respected member of prestigious scientific/medical organizations and meetings where he is often invited as a chairman.

Medicine; Genetics; Fluorine Chemistry; Nanotechnology; Biophysics; Biochemistry

Deirdre Kelly Ph.D. career spans both industry and academia where she has worked with both start-up biotech and multinational pharmaceutical companies. Dr Kelly holds a PhD (Medicine, Immunology) from the Royal College of Surgeons in Ireland, a MSc Biotechnology from the National University of Ireland, Galway, and a B.A.(Mod) Biochemistry from Trinity College, Dublin. Dr Kelly founded Kelly Scientific which is a trusted premier provider of cutting edge niche market information within the pharma, biotech and healthcare industries. Personalized medicine, targeted therapeutics, companion diagnostics and immunotherapeutics are key areas that we have significant market expertize in. We are proud to count Fortune 500 companies as many of our repeat corporate clients. Kelly Scientific provides high quality comprehensive business reports for the Pharma/Biotech industry which are updated regularly. We have scientific and business expertise in a number of therapeutic and diagnostic areas including personalized medicine, transdermal and targeted drug delivery, immunotherapy, anti-infectives, respiratory and gastrointestinal disease, genetics, pharmacogenomics, vaccines, biomarkers, biosimilars, inflammation, oncology and diabetes. We are also constantly tracking the USA, European, Russian, Chinese, Indian, Japanese and African Pharma and Biotech markets.

Personalized medicine

Adrian Llerena is the Director of the Clinical Research Center in the University Hospital Infanta Cristina en Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in two Medical Schools in the University of Extremadura Spain and part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics of antidepressant and antipsychotic drugs. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 PhD thesis

Pharmacology, Personalized Medicine

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Mind Genomics.